{"status":"success","data":{"title":"Angioedema","slug":"angioedema","tags":["ACE inhibitor,"],"collection":["Allergy-Immunology"],"content":"\n# Angioedema\n\n**Definition**: self-limited, asymmetric, localized, non-pitting swelling\n\n**Background**\n\n-   15% of population\n-   50% with urticaria\n-   *Common sites:* perioribtal, lips, tongue, extremity, bowel wall\n-   *Main cause of death:* Laryngeal edema (25-40% mortality if present)\n\n## Syndromes and Specific Treatments\n\n**Idiopathic Angioedema**\n\n-   38% of patients with angioedema\n\n**Allergic or IgE Mediated Angioedema**\n\n-   Type I hypersensitivity reaction\n-   Commonly from food or medications\n-   *Tx:* allergen avoidance, antihistamine, H2 blockers, glucocorticoid, epinephrine for laryngeal edema\n\n**Hereditary Angioedema**\n\n-   C1q esterase inhibitor deficiency\n-   *Triggers:* trauma (especially dental trauma), anxiety, menstruation, infection, exercise, alcohol consumption, stress\n-   *Prophylaxis tx:* **danazol** better than tranexamic acid and aminocaproic acid\n-   *Acute tx:*  **FFP** (or C1 inhibitor concentrate - given in Europe/Canada only)\n-   Usual IgE-mediated treatment regimen ineffective except epinephrine for laryngeal edema\n\n**ACE Inhibitor Angioedema**\n-   Up to 2.2% of those taking ACE-I's\n-   From elevated levels of bradykinin\n-   Highest incidence during 1st month of starting medication, but can occur years after \n-   5x more common in African-Americans compared to Caucasians\n-   Controversial whether patient can take ARBs (doesn’t cause elevated bradykinin) as well – some with angioedema.\n-   *Tx: * discontinue medication and supportive care\n-   Usual IgE-mediated treatment regimen ineffective except epinephrine for laryngeal edema\n\n**Treatment philosophy:** \n\n-   Low threshold to protect airway by intubation\n-   ***Pearl:*** Be sure to prescribe patients Epi-pen if discharged home\n-   *Fiberoptic nasopharyngoscopy*: consider performing on all patients with voice change to look for largnyeal edema\n\n## Admission guidelines for angioedema\n\n([Ishoo et al., Head Neck Surg, 1999](https://www.ncbi.nlm.nih.gov/pubmed/?term=18374684))  \n\n-   93 episodes in 80 patients (1985-95) with no deaths \n-   9.7% cases required intubation/tracheostomy\n-   *Causes:* 39% from <span class=\"drug\">ACE-I</span>\n-   *Disposition:* 25% outpt, 23% floor, 53% ICU\n-   ICU admissions correlated with voice change, hoarseness, dyspnea, rash \n-   Airway intervention correlated with voice change, hoarseness, dyspnea, stridor\n\n**Proposed staging system:**\n\n-   **Stage I:** Facial rash, facial edema, lip edema - outpatient\n-   **Stage II**: Soft palate edema – outpatient or floor\n-   **Stage III:** Lingual edema --&gt; ICU (7% required airway intervention)\n-   **Stage IV:** Laryngeal edema –&gt; ICU (24% required airway intervention)\n\n## References\n\n-   [Ishoo E et al. Predicting airway risk in angioedema: Staging system based on presentation. Otolaryngol Head Neck Surg 1999; 121:263-8.](https://www.ncbi.nlm.nih.gov/pubmed/?term=18374684)\n-   [Temino VM, Peebles RS. Spectrum and Treatment of Angioedema. Am J Med 2008; 121: 282-6](https://www.ncbi.nlm.nih.gov/pubmed/?term=18374684)\n-   [Emedicine.com](http://emedicine.medscape.com/)\n"}}